The HCV NS3/4A serine protease inhibitors (PIs) boceprevir (BOC), telaprevir (TVR) and simeprevir (SMV) are approved for treatment of chronic hepatitis C infection in combination with pegylated interferon and ribavirin. The present study investigated the prevalence of HCV NS3 drug resistance mutations (DRMs) associated with HCV genotype-1-infected individuals at baseline and in viral breakthrough following BOC and TVR treatment.
Methods
HCV genotype-1-infected individuals were enrolled in a multicentre, prospective outcomes study. The HCV NS3 viral protease was analysed for DRMs at baseline (n=164) and at viral breakthrough (n=18) following BOC/ TVR treatment.
Results
Viral NS3 protease subtype analysis showed 65.2% (107/164) were HCV subtype-1a and 34.8% (57/164) were HCV subtype-1b infections. Naturally occurring PI DRMs in NS3 (V36L, T54S, V55A, Q80K/R and I132V) were identified in 57.3% (94/164) cases at baseline. The NS3 Q80K polymorphism was found in 43/107 (40.2%) of HCV subtype-1a and exclusively in clade 1 (43/82; 52.4%) versus clade 2 viruses (0/25; 0%, P<10-6). The pretreatment I132V variant was found in 78.9% (45/57) of subtype-1b. Of 18 patients who had viral breakthrough, the majority was subtype-1a (77.8%, 14/18). BOC/TVR-associated DRMs were detected in 94.4% (17/18), of which 64.7% (11/17) emerged on-treatment.
Conclusions
To ensure the most appropriate direct-acting antiviral-based treatment regimen is employed, baseline reporting of clade and resistance mutations for HCV sub-type-1a using nucleotide sequence-based analysis is warranted prior to commencement of therapy.
References
1.
ButtA.A., KanwalF.Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.Clin Infect Dis2012; 54: 96–104.
2.
MooreC., LevitskyJ.The current state and future prospects of chronic hepatitis C virus infection treatment.Curr Infect Dis Rep2014; 16: 413.
3.
SchneiderM.D., SarrazinC.Antiviral therapy of hepatitis C in 2014: do we need resistance testing?Antiviral Res2014; 105: 64–71.
4.
VicentiI., RosiA., SaladiniF.Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.J Antimicrob Chemother2012; 67: 984–987.
5.
PaolucciS., FiorinaL., PirallaA.Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients.Virol J2012; 9: 245.
6.
LeggewieM., SreenuV.B., AbdelrahmanT.Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C.AIDS2013; 15: 2485–2488.
7.
PalanisamyN., DanielssonA., KokkulaC.Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis C virus genotypes 1a, 2b and 3a.Antiviral Res2013; 99: 12–17.
8.
AndonovA., KadkhodaK., OsiowyC., KaitaL.Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C subgenotype 1a-infected patients from Manitoba.Can J Gastroenterol2013; 27: 414–416.
9.
NishiyaA.S., De Almeida-NetoC., FerreiraS.C.HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood Donors in Sao Paulo, Brazil.PLoS ONE2014; 9: e86413.
10.
EhretR., NeiferS., WalterH., BaumgartenA., ObermeierM.Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV/HCV co-infected patients in a Berlin laboratory.J Int AIDS Soc2014; 17Suppl 3: 19741.
11.
EASL.EASL Clinical Practice Guidelines: management of hepatitis C virus infection.J Hepatol2014; 60: 392–420.
12.
BergerK.L., TrikiI., CartierM.Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.Antimicrob Agents Chemother2014; 58: 698–705.
13.
LenzO., FeveryB., VerbinnenT.Resistance analyses of HCV isolates from patients treated with simeprevir in Phase IIB/III studies.Hepatology2013; 58: 743A.
14.
PickettB.E., StrikerR., LefkowitzE.J.Evidence for separation of HCV subtype 1a into two distinct clades.J Viral Hepat2011; 18: 608–618.
15.
De LucaA., Di GiambenedettoS., ProsperiM.Two distinct HCV genotype 1a clades: geographical distribution and association with natural resistance mutations to HCV NS3/4A inhibitors.Antivir Ther2013; 18Suppl 1: A47.
16.
ManiN.Clinically relevant HCV drug resistance mutations figure and tables.Annals of the Forum for Collaborative HIV Research2012; 14: 1–10.
17.
WylesD.L.Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection.Top Antivir Med2012; 20: 139–145.
18.
AnsaldiF., OrsiA., SticchiL., BruzzoneB., IcardiG.Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.World J Gastroenterol2014; 20: 9633–9652.
19.
BoglioneL., De NicoloA., CardellinoC.S.Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy.Clin Microbiol Infect2015. 21: 205e1–3.
20.
KiefferT.L., GeorgeS.Resistance to hepatitis C virus protease inhibitors.Curr Opin Virol2014; 8: 16–21.
21.
VermehrenJ., SarrazinC.The role of resistance in HCV treatment.Best Pract Res Clin Gastroenterol2012; 26: 487–503.
22.
LarratS., KulkarniO., ClaudeJ.B.Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients.J Clin Microbiol2015; 53: 389–397.
23.
TrimouletP., PinsonP., PapuchonJ.Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy.Antivir Ther2013; 18: 723–727.
